Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Introduction
Loss of neutrophils causes disruption of immune defense mechanisms and increases the likelihood for infections. Neutropenia is frequently associated with cancer chemotherapy and developed by majority of cancer patients during chemotherapy.
Chemotherapy treatments for cancer are well-known to be associated with a depletion of white blood cells, in particular neutrophils, causing a condition known as chemotherapy- -induced neutropenia (CIN)
Access Full Report @ https://www.transparencymarketresearch.com/chemotherapyinduced-neutropenia-cin-treatment-market.html
Chemotherapy-induced neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy
There are ways to manage CIN such as delaying and reducing chemotherapy treatment with hematopoietic growth factors and with intravenous antibiotic therapy
Key Drivers and Restraints of Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market
Rise in prevalence of cancer across the globe and increase in use of chemotherapy are major drivers of the global chemotherapy-induced neutropenia (CIN) treatment market
For instance, as per Glubocan data, total 1,80,78,957 new cancer patients were reported to suffer any form of cancer across the globe
Robust R&D activities by major companies in the development of novel therapeutics is also fueling the global chemotherapy-induced neutropenia (CIN) treatment market
Moreover, an increase in government funding for life-threatening diseases across the world is also a key factor driving the global chemotherapy-induced neutropenia (CIN) treatment market
Request Brochure of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79518
Antibiotic Therapy Segment Dominated Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market
In terms of type, the global chemotherapy-induced neutropenia (CIN) treatment market can be divided into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, splenectomy procedure, and others
The antibiotic therapy accounted for a major share of the global market in 2019 owing to quicker action, high range availability, and launch of new products in the last few years
Online Pharmacies Segment to Witness Significant Growth
In terms of distribution channel, the global chemotherapy-induced neutropenia (CIN) treatment market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies
The retail pharmacies segment held a major share of the global market, in terms of revenue, in 2019. The trend is expected to continue during the forecast period. Inclusion of various medicines under the OTC category and preference for self-medication are projected to drive the segment.
However, the online pharmacies segment is likely to expand at a notable CAGR from 2020 to 2030 due to an increase in Internet penetration and smartphone ownership along with the ease of ordering medications through an e-commerce platform, and better discounted rates
Request for Analysis of COVID-19 Impact on Chemotherapy-Induced Neutropenia (CIN) Treatment Market @ https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79518
North America to Dominate Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market
In terms of region, the global chemotherapy-induced neutropenia (CIN) treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
In terms of revenue, North America dominated the global chemotherapy-induced neutropenia (CIN) treatment market in 2019 due to a rise in prevalence of different types of cancer, rise in government funding for research, and increase in cases of chemotherapy induced side-effects among cancer survivors
For instance, as per National Cancer Institute, around 1,806,590 new cases of cancer are estimated to be diagnosed in the U.S. in 2020
Asia Pacific is likely to be a highly lucrative market for chemotherapy-induced neutropenia (CIN) treatment during the forecast period. The market in the region is projected to expand at a high CAGR from 2020 to 2030.
Higher patient population, adoption of new treatment methods, pipeline drugs, and increase in awareness regarding chemotherapy-induced neutropenia (CIN) are anticipated to propel the market in Asia Pacific during the forecast period
Make an Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=79518
Key players Operating in Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market
The global chemotherapy-induced neutropenia (CIN) treatment market was highly fragmented in 2019. Key players operating in the global market are:
- Amgen, Inc
- Novartis AG
- Sanofi
- Biogenomics Limited
- Baxter International
- Dr. Reddy’s Laboratory Ltd.
- Apotex, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Ligand Pharmaceuticals, Inc.
- Coherus BioSciences, Inc.
Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Research Scope
Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Type
- Antibiotic Therapy
- Colony-Stimulating Factor Therapy
- Granulocyte Transfusion
- Splenectomy Procedure
- Others
Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
More Related Reports by Transparency Market Research –
Hemostasis Diagnostic Analyzers and Reagents Market: https://www.transparencymarketresearch.com/hemostasis-diagnostic-analyzers-reagents-market.html
Fragile X Syndrome Market: https://www.transparencymarketresearch.com/fragile-x-syndrome-market.html
Transthyretin Amyloidosis Treatment Market: https://www.transparencymarketresearch.com/transthyretin-amyloidosis-treatment-market.html
Chemotherapy Drugs Market: https://www.transparencymarketresearch.com/chemotherapy-drugs-market.html
Acquired Hemophilia Therapeutics Market: https://www.transparencymarketresearch.com/acquired-hemophilia-therapeutics-market.html
Pulmonary Edema Therapeutics Market: https://www.transparencymarketresearch.com/pulmonary-edema-therapeutics-market.html
About Us
Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact Us
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
